MedCity News March 19, 2025
Ampersand Biomedicines’ map of all tissue in the human body reveals “addresses,” identifying markers on disease targets that are not found on healthy tissue. The company aims to improve the targeting of biologic drugs in order to reduce on-target, off-tissue toxicity.
Just as a map shows you how to reach a destination in the real world, Ampersand Biomedicines’ map of tissues of the human body shows where a drug should go in the biological one. Now the startup has $65 million to continue its journey with programs progressing in cancer and inflammation.
The Series B financing announced Wednesday comes two years after the Boston-based biotech launched from the labs of Flagship Pioneering. Joining Flagship in the latest round is new...
Today's Sponsors
Today's Sponsor